================================================================================
COLLECTED CLINICAL TRIALS REPORT
================================================================================
Collection Date: 2025-07-18 16:39:24
Total Studies: 45
Search Query: AREA[Condition](Neuroendocrine Tumors OR Carcinoma Neuroendocrine OR Carcinoid Tumor) AND AREA[PrimaryCompletionDate] RANGE[2020-01-01,MAX] AND AREA[OverallStatus](ACTIVE_NOT_RECRUITING) AND NOT AREA[Phase]Phase 1 AND (AREA[HasResults] false)
Filter Criteria: Studies with results posted from 2020 onwards, excluding Phase 1, with publications
--------------------------------------------------------------------------------

1. Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
   NCT ID: NCT04754425
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Castration-Resistant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Adenocarcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
   Intervention: Biopsy; Biospecimen Collection; Erdafitinib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2021-07-15
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04754425
   Summary: This phase II trial studies the effect of erdafitinib in treating patients with prostate cancer that grows and continues to spread despite the surgical removal of the testes or drugs to block androgen production (castration-resistant). Erdafitinib may stop the growth of tumor cells by blocking some ...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

2. Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
   NCT ID: NCT03360721
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma Without Neuroendocrine Differentiation; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
   Intervention: Abiraterone Acetate; Apalutamide; Prednisone
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2018-03-06
   Completion Date: 2027-04-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03360721
   Summary: This phase II trial studies how well apalutamide and abiraterone acetate work in treating participants with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abiraterone acetate and apalutamide may stop the growth of tumor cells by blocking some of the en...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

3. Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
   NCT ID: NCT03891784
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Digestive System Neuroendocrine Neoplasm; Digestive System Neuroendocrine Tumor; Foregut Neuroendocrine Tumor; Hindgut Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Neoplasm; Midgut Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Refractory Digestive System Neuroendocrine Neoplasm
   Intervention: Abemaciclib
   Sponsor: University of Washington
   Start Date: 2019-10-31
   Completion Date: 2027-09-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03891784
   Summary: This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the ...
   Locations: University of Colorado, Denver, United States; Fred Hutch/University of Washington Cancer Consortium, Seattle, United States
----------------------------------------

4. Post-Authorization Long-Term Safety Study of LUTATHERA
   NCT ID: NCT03691064
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: LUTATHERA
   Sponsor: Advanced Accelerator Applications
   Start Date: 2018-11-28
   Completion Date: 2028-06-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03691064
   Summary: Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
   Locations: Banner MD Anderson Cancer Center, Phoenix, United States; The Ohio State University Wexner Medical Center, Portland, United States; Oregon Health & Sciences University Hospital, Portland, United States
              ... and 17 more locations
----------------------------------------

5. Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
   NCT ID: NCT04727723
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Gastroenteropancreatic Neuroendocrine Tumor
   Intervention: Lutathera®
   Sponsor: Advanced Accelerator Applications
   Start Date: 2021-03-09
   Completion Date: 2025-04-01
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04727723
   Summary: This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed Lutathera® in standard clinical practice.
   Locations: Novartis Investigative Site, Alessandria, Italy; Novartis Investigative Site, Bologna, Italy; Novartis Investigative Site, Brescia, Italy
              ... and 15 more locations
----------------------------------------

6. A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
   NCT ID: NCT04524208
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Neuroendocrine Carcinoma
   Intervention: Cabozantinib
   Sponsor: Karsten Gavenis
   Start Date: 2021-03-01
   Completion Date: 2024-10-31
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04524208
   Summary: The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.
   Locations: Medizinische Universität Wien, Wien, Austria; University Medical Center Göttingen, Göttingen, Germany; Zentralklinik Bad Berka GmbH, Bad Berka, Germany
              ... and 12 more locations
----------------------------------------

7. Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
   NCT ID: NCT05064514
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Tricuspid Regurgitation; Tricuspid Valve Disease; Carcinoid Syndrome; Carcinoid Heart Disease
   Intervention: Transcatheter Tricuspid Valved Stent Graft
   Sponsor: Queen Mary University of London
   Start Date: 2022-04-06
   Completion Date: 2028-03
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05064514
   Summary: The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and who are not able to have a new valve via a surgical procedure.
   Locations: Barts Health NHS Trust, London, United Kingdom
----------------------------------------

8. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
   NCT ID: NCT04584008
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Biliary Tract Neoplasms; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Colorectal Cancer; Gastrointestinal Stromal Tumors; Pancreatic Cancer; Neuroendocrine Tumors; Unknown Primary Cancer; Digestive Cancer
   Intervention: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.; Other Therapy
   Sponsor: Peking University
   Start Date: 2020-09-23
   Completion Date: 2025-03
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04584008
   Summary: This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and complex, to screen potential molecular targeted drugs for individualized ...
   Locations: Peking University Cancer Hospital, Beijing, China
----------------------------------------

9. Neuroendocrine Tumors - Patient Reported Outcomes
   NCT ID: NCT05064150
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors; Gastroenteropancreatic Neuroendocrine Tumor; Lung Neuroendocrine Neoplasm; Neuroendocrine Carcinoma
   Intervention: 
   Sponsor: University of Iowa
   Start Date: 2022-05-10
   Completion Date: 2026-06
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05064150
   Summary: With so many therapeutic options available (i.e.: biologic therapy, liver directed therapy, radiotherapy and chemotherapy), the purpose of this project is to partner with patients on comparative effectiveness research (CER) to achieve the goal of alleviating undue toxicity, and optimizing effectiven...
   Locations: University of Florida, Gainesville, United States; University of Iowa, Iowa City, United States; University of Kansas Medical Center Research Institute, Inc, Kansas City, United States
              ... and 11 more locations
----------------------------------------

10. Combination Immunotherapy in Rare Cancers Under InvesTigation
   NCT ID: NCT04969887
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor
   Intervention: Ipilimumab; Nivolumab
   Sponsor: Olivia Newton-John Cancer Research Institute
   Start Date: 2021-08-03
   Completion Date: 2028-03
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04969887
   Summary: The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups:

1. Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and G...
   Locations: Border Medical Oncology Unit, Albury, Australia; Orange Health Service, Orange, Australia; Blacktown Hospital, Sydney, Australia
              ... and 15 more locations
----------------------------------------

11. Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
   NCT ID: NCT05153772
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: AlphaMedix
   Sponsor: Orano Med LLC
   Start Date: 2021-12-21
   Completion Date: 2028-10
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05153772
   Summary: Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)
   Locations: Rocky Mountain Cancer Center, Denver, United States; Moffitt Cancer Center, Tampa, United States; Louisiana State University (LSU) Health Sciences Center - New Orleans, Metairie, United States
              ... and 1 more locations
----------------------------------------

12. Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
   NCT ID: NCT04079712
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Neuroendocrine Carcinoma
   Intervention: Cabozantinib S-malate; Ipilimumab; Nivolumab
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2020-08-06
   Completion Date: 2026-07-14
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04079712
   Summary: This phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look like the normal tissue it arose from). Cabozantinib may stop the growth of...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; Banner University Medical Center - Tucson, Tucson, United States; University of Arizona Cancer Center-North Campus, Tucson, United States
              ... and 43 more locations
----------------------------------------

13. EchoTip AcuCore Post-Market Clinical Study
   NCT ID: NCT06358001
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis
   Intervention: EchoTip AcuCore
   Sponsor: Cook Research Incorporated
   Start Date: 2024-08-05
   Completion Date: 2025-09-01
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06358001
   Summary: The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.
   Locations: University of California, Irvine, Orange, United States; Advent Health, Porter, Denver, United States; Shands Hospital-University of Florida, Gainesville, United States
              ... and 5 more locations
----------------------------------------

14. Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
   NCT ID: NCT03498040
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Carcinoid Heart Disease
   Intervention: Study of the occurrence of Carcinoid Heart Disease
   Sponsor: Hospices Civils de Lyon
   Start Date: 2018-04-16
   Completion Date: 2033-04-16
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03498040
   Summary: Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of disease remain unclear.

This observational multicenter cohort study is desig...
   Locations: CHU Amiens, Amiens, France; CHU Angers, Angers, France; CHU Bordeaux - Hopital Haut-Lévèque, Bordeaux, France
              ... and 16 more locations
----------------------------------------

15. Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
   NCT ID: NCT05361668
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; Carcinoid Syndrome Diarrhea; Carcinoid Intestine Tumor; Carcinoid Tumor of Liver; Carcinoid Tumor of Pancreas
   Intervention: Randomized: 40 mg Paltusotine; Randomized: 80 mg Paltusotine
   Sponsor: Crinetics Pharmaceuticals Inc.
   Start Date: 2022-06-17
   Completion Date: 2026-02
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05361668
   Summary: The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
   Locations: Crinetics Study Site, Los Angeles, United States; Crinetics Study Site, Los Angeles, United States; Crinetics Study Site, Newport Beach, United States
              ... and 32 more locations
----------------------------------------

16. A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
   NCT ID: NCT05470595
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Large Cell Neuroendocrine Carcinoma of the Lung
   Intervention: Atezolizumab
   Sponsor: Technische Universität Dresden
   Start Date: 2022-01-18
   Completion Date: 2029-01-31
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05470595
   Summary: This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
   Locations: Charité - Universitätsklinikum Berlin Centrum 12, Medizinische Klinik, Berlin, Germany; Evangelische Lungenklinik, Berlin, Germany; Universitätsklinikum Dresden, Medizinische Klinik 1, Dresden, Germany
              ... and 12 more locations
----------------------------------------

17. Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
   NCT ID: NCT06908629
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Cancer; Cancer Survivors; Gastrointestinal Cancers; Neuroendocrine Tumors; Multiple Myeloma, Neoplasms
   Intervention: Implementation of social determinants of health screening and referral
   Sponsor: Barbara Ann Karmanos Cancer Institute
   Start Date: 2024-07-01
   Completion Date: 2025-05
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06908629
   Summary: The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are:

* Can we have a completion rate of at least 80% of participan...
   Locations: Karmanos Cancer Institute, Detroit, United States
----------------------------------------

18. Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
   NCT ID: NCT02595424
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Gastric Neuroendocrine Carcinoma; Intestinal Neuroendocrine Carcinoma; Pancreatic Neuroendocrine Carcinoma
   Intervention: Capecitabine; Carboplatin; Cisplatin; Etoposide; Laboratory Biomarker Analysis; Temozolomide
   Sponsor: ECOG-ACRIN Cancer Research Group
   Start Date: 2016-04-06
   Completion Date: 2029-01-01
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02595424
   Summary: This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metas...
   Locations: Kingman Regional Medical Center, Kingman, United States; Cancer Center at Saint Joseph's, Phoenix, United States; Mercy Hospital Fort Smith, Fort Smith, United States
              ... and 670 more locations
----------------------------------------

19. Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
   NCT ID: NCT02743741
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: Lutetium-177 Octreotate
   Sponsor: University Health Network, Toronto
   Start Date: 2016-07-15
   Completion Date: 2026-06
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02743741
   Summary: This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuro...
   Locations: Juravinski Cancer Centre, Hamilton, Canada; London Health Sciences Centre, London, Canada; Princess Margaret Cancer Centre, Toronto, Canada
              ... and 1 more locations
----------------------------------------

20. A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
   NCT ID: NCT06148636
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas
   Intervention: [212Pb] VMT-α-NET; [203Pb] VMT-α-NET SPECT/CT
   Sponsor: David Bushnell
   Start Date: 2023-11-10
   Completion Date: 2027-11-20
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06148636
   Summary: This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
   Locations: Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, United States
----------------------------------------

21. Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
   NCT ID: NCT03600233
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Pancreatic Neuroendocrine Tumor; Gastro-enteropancreatic Neuroendocrine Tumor; Lung Neuroendocrine Neoplasm; Neuroendocrine Carcinoma
   Intervention: CVM-1118
   Sponsor: TaiRx, Inc.
   Start Date: 2018-12-15
   Completion Date: 2025-12-31
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03600233
   Summary: CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objecti...
   Locations: Chang Gung Memorial Hospital, KaoHsiung, Kaohsiung, Taiwan; Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
              ... and 5 more locations
----------------------------------------

22. A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET
   NCT ID: NCT05050942
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Gastro-enteropancreatic Neuroendocrine Tumor
   Intervention: CAM2029; Octreotide LAR; Lanreotide ATG
   Sponsor: Camurus AB
   Start Date: 2021-10-22
   Completion Date: 2027-12
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05050942
   Summary: The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with...
   Locations: Mayo Clinic Cancer Center (MCCC) - Phoenix, Phoenix, United States; UCLA Ahmanson Biological Imaging Center, Santa Monica, United States; Rocky Mountain Cancer Centers - Denver - Midtown, Denver, United States
              ... and 95 more locations
----------------------------------------

23. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
   NCT ID: NCT04919226
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT; CAPTEM (Capecitabine and Temozolomide); Amino-Acid Solution; Everolimus; FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
   Sponsor: ITM Solucin GmbH
   Start Date: 2021-12-21
   Completion Date: 2027-09
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04919226
   Summary: The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, soma...
   Locations: Stanford Cancer Center, Palo Alto, United States; University of Colorado Hospital, Nuclear Medicine, Aurora, United States; H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
              ... and 39 more locations
----------------------------------------

24. Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
   NCT ID: NCT03457948
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Malignant Neoplasm in the Liver; Neuroendocrine Neoplasm
   Intervention: Arterial Embolization; Pembrolizumab; Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate; Yttrium-90 Microsphere Radioembolization
   Sponsor: Nicholas Fidelman, MD
   Start Date: 2018-08-27
   Completion Date: 2026-12-31
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03457948
   Summary: This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver (liver metastases). Immuno...
   Locations: University of California, San Francisco, San Francisco, United States
----------------------------------------

25. 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
   NCT ID: NCT05448157
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumor Carcinoid; Neuroendocrine Tumor of Pancreas; Gep Net
   Intervention: 
   Sponsor: European Institute of Oncology
   Start Date: 2022-05-12
   Completion Date: 2023-12-12
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05448157
   Summary: In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates. In GEP-NETs the actual surgical planning is established on the ground of preoperative morphology images (CT scan), and functional imaging using CT/PET with 68Ga-DOT...
   Locations: IRCCS Istituto Europeo di Oncologia S.r.l., Milan, Italy
----------------------------------------

26. Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
   NCT ID: NCT01763554
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors, NET
   Intervention: Lu-177 DOTA-TATE
   Sponsor: AHS Cancer Control Alberta
   Start Date: 2012-08
   Completion Date: 2025-12
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01763554
   Summary: Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data wil...
   Locations: Cross Cancer Institute, Edmonton, Canada
----------------------------------------

27. Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
   NCT ID: NCT04848337
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Prostate Cancer Metastatic; Neuroendocrine Tumors
   Intervention: Pembrolizumab; Lenvatinib
   Sponsor: University of Michigan Rogel Cancer Center
   Start Date: 2021-05-25
   Completion Date: 2025-12
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04848337
   Summary: Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On D...
   Locations: City of Hope, Duarte, United States; Winship Cancer Instituted of Emory University, Atlanta, United States; University of Michigan Health System, Ann Arbor, United States
              ... and 2 more locations
----------------------------------------

28. Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
   NCT ID: NCT04592237
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8
   Intervention: Cabazitaxel; Carboplatin; Cetrelimab; Niraparib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2020-12-29
   Completion Date: 2025-12-31
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04592237
   Summary: This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cabazitaxel and carbo...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

29. Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
   NCT ID: NCT04291885
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Merkel Cell Carcinoma; Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Merkel Cell Carcinoma, Stage III; Neuroendocrine Tumors; Carcinoma Neuroendocrine Skin
   Intervention: Avelumab; Placebo
   Sponsor: Melanoma and Skin Cancer Trials Limited
   Start Date: 2020-10-26
   Completion Date: 2030-04-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04291885
   Summary: The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.
   Locations: Port Macquarie Base Hospital, Port Macquarie, Australia; Chris O'Brien Lifehouse, Sydney, Australia; Melanoma Institute Australia, Sydney, Australia
              ... and 17 more locations
----------------------------------------

30. A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
   NCT ID: NCT05459844
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: Lutetium[177Lu] Oxodotreotide Injection; Octreotide LAR
   Sponsor: Sinotau Pharmaceutical Group
   Start Date: 2022-08-31
   Completion Date: 2028-12
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05459844
   Summary: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\[177Lu\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2)...
   Locations: Chinese PLA General Hospital, Beijing, China; The First Afilliated Hospital of Fujian Medical University, Fuzhou, China; The First Affiliated Hospital of Xiamen University, Xiamen, China
              ... and 20 more locations
----------------------------------------

31. Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
   NCT ID: NCT04810091
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Locally Advanced Neuroendocrine Neoplasm; Metastatic Neuroendocrine Neoplasm
   Intervention: Placebo Administration; Questionnaire Administration; Telotristat Ethyl
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2021-05-18
   Completion Date: 2025-08-26
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04810091
   Summary: This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to other places in the body (metastatic). Telotristat ethyl and somatostatin ...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

32. Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
   NCT ID: NCT03049189
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: 177Lu-edotreotide PRRT; Everolimus; Amino-Acid Solution
   Sponsor: ITM Solucin GmbH
   Start Date: 2017-02-02
   Completion Date: 2029-11
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03049189
   Summary: The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastro...
   Locations: Banner Health d.b.a. Banner MD Anderson Cancer Center, Gilbert, United States; Stanford University, Stanford, United States; Moffitt Cancer Center & Research Institute, Tampa, United States
              ... and 49 more locations
----------------------------------------

33. Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
   NCT ID: NCT03950609
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Multiple Endocrine Neoplasia Type 1; Neuroendocrine Neoplasm; Unresectable Carcinoid Tumor
   Intervention: Everolimus; Lenvatinib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2019-07-30
   Completion Date: 2026-03-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03950609
   Summary: This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

34. A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
   NCT ID: NCT05111509
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor Grade 1
   Intervention: [203Pb]VMT-α-NET; SPECT/CT
   Sponsor: Yusuf Menda
   Start Date: 2022-08-22
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05111509
   Summary: This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.
   Locations: The University of Iowa, Iowa City, United States
----------------------------------------

35. Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
   NCT ID: NCT04701307
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Lung Small Cell Carcinoma; Neuroendocrine Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
   Intervention: Dostarlimab; Niraparib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2021-02-01
   Completion Date: 2025-11-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04701307
   Summary: This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cance...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

36. Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
   NCT ID: NCT04804371
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Neuroendocrine Tumors
   Intervention: F18-FDG
   Sponsor: University Health Network, Toronto
   Start Date: 2021-03-04
   Completion Date: 2026-02-22
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04804371
   Summary: The variable clinical outcome of patients with G2 \& G3 well diff GEP-NETs makes the selection of an optimal treatment strategy challenging.

Initial data suggests that high DOTATATE uptake and low FDG uptake are suggestive of low grade disease, with an indolent course.

Conversely, low DT uptake an...
   Locations: Princess Margaret Cancer Centre, Toronto, Canada
----------------------------------------

37. Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
   NCT ID: NCT03110978
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Lung Atypical Carcinoid Tumor; Lung Neuroendocrine Neoplasm; Lung Non-Small Cell Squamous Carcinoma; Minimally Invasive Lung Adenocarcinoma; Neuroendocrine Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Large Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8
   Intervention: Nivolumab; Stereotactic Body Radiation Therapy
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2017-06-26
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03110978
   Summary: This phase II trial studies how well stereotactic body radiation therapy with or without nivolumab works in treating patients with stage I-IIA non-small cell lung cancer or cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiati...
   Locations: MD Anderson in The Woodlands, Conroe, United States; M D Anderson Cancer Center, Houston, United States; MD Anderson West Houston, Houston, United States
----------------------------------------

38. Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
   NCT ID: NCT06204159
   Status: ACTIVE_NOT_RECRUITING
   Phase: NA
   Condition: Hepatocellular Carcinoma; Neuroendocrine Tumors
   Intervention: TACE Catheters
   Sponsor: Abramson Cancer Center at Penn Medicine
   Start Date: 2024-02-01
   Completion Date: 2026-06-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06204159
   Summary: The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure. Both catheters are FDA approved for delivery of TACE.

• Is there a difference in CT appearance with deliv...
   Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, United States; University of Pennsylvania, Department of Radiology, Interventional Radiology Division, Philadelphia, United States
----------------------------------------

39. Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma
   NCT ID: NCT03022188
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors
   Intervention: 
   Sponsor: Société Française d'Endoscopie Digestive
   Start Date: 2017-01-10
   Completion Date: 2026-12
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03022188
   Summary: Neuroendocrine tumors (NETs) and carcinomas account for 10-15 % of all pancreatic incidentalomas. The management of pancreatic NETs depends on tumor stage and on presence or not of hormonal syndrome. The therapeutic approach for hormonally functional tumor, or large tumor (\> 2 cm) with local, vascu...
   Locations: Clinique Universitaire Saint Luc, Louvain, Belgium; Hopital Sud, Amiens, France; CHU Angers, Angers, France
              ... and 19 more locations
----------------------------------------

40. Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
   NCT ID: NCT04869137
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Merkel Cell Carcinoma; Neuroendocrine Carcinoma of the Skin; Trabecular Carcinoma of the Skin
   Intervention: Lenvatinib Oral Product; Pembrolizumab
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2021-05-28
   Completion Date: 2026-09
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04869137
   Summary: This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.
   Locations: Moffitt Cancer Center, Tampa, United States
----------------------------------------

41. Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
   NCT ID: NCT05247905
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Pancreatic Neuroendocrine Tumor; Unresectable Pancreatic Neuroendocrine Carcinoma
   Intervention: Lutetium Lu 177 Dotatate; Capecitabine; Temozolomide; Quality-of-Life Assessment; Questionnaire Administration
   Sponsor: Alliance for Clinical Trials in Oncology
   Start Date: 2023-02-16
   Completion Date: 2033-10-01
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05247905
   Summary: This phase II trial compares capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or are not able to be removed by surgery (unresectable). Chemotherapy drugs, such as capecitabine and te...
   Locations: Fairbanks Memorial Hospital, Fairbanks, United States; Mayo Clinic Hospital in Arizona, Phoenix, United States; Tower Cancer Research Foundation, Beverly Hills, United States
              ... and 168 more locations
----------------------------------------

42. Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
   NCT ID: NCT04544098
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Neuroendocrine Tumors; Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
   Intervention: 177Lu-DOTATATE
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2020-09-02
   Completion Date: 2026-09
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04544098
   Summary: This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

43. Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
   NCT ID: NCT03902951
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Recurrent Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
   Intervention: Abiraterone Acetate; Apalutamide; Leuprolide Acetate; Quality-of-Life Assessment; Questionnaire Administration; Stereotactic Body Radiation Therapy
   Sponsor: Jonsson Comprehensive Cancer Center
   Start Date: 2021-03-17
   Completion Date: 2027-01-01
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03902951
   Summary: This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating patients with prostate cancer that has come back and has spread to other parts of the body. Drugs used in chemotherapy, such a...
   Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, United States
----------------------------------------

44. DOTATOC PET/CT for Imaging NET Patients
   NCT ID: NCT03583528
   Status: ACTIVE_NOT_RECRUITING
   Phase: N/A
   Condition: Neuroendocrine Tumors; Insulinoma; Gastrinoma; Glucagonoma; Vipoma; Pheochromocytoma; Paraganglioma; Neuroblastoma; Ganglioneuroma; Medullary Carcinoma; Pituitary Adenoma; Medulloblastoma; Merkel Cell Carcinoma; Small-cell Lung Cancer; Meningioma; Carcinoid
   Intervention: 68Ga-DOTATOC PET/CT; 18F-FDG PET/CT
   Sponsor: British Columbia Cancer Agency
   Start Date: 2018-07-11
   Completion Date: 2028-09-30
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03583528
   Summary: Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventi...
   Locations: BC Cancer, Vancouver, Canada
----------------------------------------

45. An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
   NCT ID: NCT04993261
   Status: ACTIVE_NOT_RECRUITING
   Phase: EARLY_PHASE1
   Condition: Carcinoid Syndrome; Carcinoid Tumor; Digestive System Neuroendocrine Tumor G1; Metastatic Carcinoid Tumor
   Intervention: Dual-Energy Computed Tomography
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-09-23
   Completion Date: 2026-12-31
   Has Posted Results: False
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04993261
   Summary: This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during ro...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

